Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis in merger talks with Genzyme

Sanofi-aventis has announced that it is in discussions with Genzyme, and has offered to acquire the company for $18.5bn, or $69 a share

Sanofi-aventis (S-A) has announced that it is in discussions with Genzyme, producer of drugs for rare diseases and has offered to acquire the company for $18.5bn, or $69 a share. Genzyme has stated that the figure is too low and the two companies are looking at a way to bridge the valuation gap with a potential contingent value right (CVR) for multiple sclerosis drug alemtuzumab, which the US biotech company plans to brand as Lemtrada.

S-A first sent a letter to Genzyme's management last July. It launched the tender offer, which expires on January 21, after failing to engage Genzyme executives in talks.

Financial advisers for the two companies are discussing the value of a CVR that would take the total Genzyme offer to around $80 per share from $69 at present if it meets certain milestones, giving the US target a total value of $20.7bn.

A representative from S-A said: "Those discussions are continuing and now include representatives from both companies. There remain significant differences on the terms and conditions of the potential CVR and the value of our offer, and there is no guarantee that the parties will come to an agreement."

A contingent value right, or CVR, is often used when buyers and sellers can't agree on a purchase price and usually kicks in after an acquired company meets sales or regulatory targets.

10th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics